Form 4: Nuvalent CFO Balcom Exercises, Sells Stock

Nuvalent CFO Alexandra Balcom executed planned stock option exercises and subsequent sales of Class A Common Stock totaling over $3.3 million under a Rule 10b5-1 trading plan.

Summary

• Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), engaged in transactions involving the company's Class A Common Stock on October 13 and 14, 2025.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Balcom acquired a total of 40,000 shares of Class A Common Stock through the exercise of stock options.
• The acquired shares consisted of 6,875 shares at an exercise price of $6.89, 13,125 shares at $18.93, and an additional 20,000 shares at $18.93.
• The total cost for exercising these options was approximately $674,575.
• Concurrently, Balcom disposed of a total of 40,000 shares of Class A Common Stock through multiple sales transactions.
• The sales occurred at weighted average prices ranging from $85.75 to $89.22 per share.
• The total proceeds from the sale of these shares amounted to approximately $3,493,327.70.
• Following these transactions, Balcom's direct beneficial ownership of Class A Common Stock remained at 61,734 shares.
• Remaining derivative securities include 35,976 stock options with a strike price of $6.89 and 30,662 stock options with a strike price of $18.93.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction under a pre-established Rule 10b5-1 trading plan, primarily reflecting the monetization of vested equity compensation rather than a change in company fundamentals or outlook.

Positives

• The Chief Financial Officer monetized vested equity compensation, indicating a significant personal gain from the company's stock performance.
• The sales prices for the Class A Common Stock (ranging from $85.75 to $89.22) are substantially higher than the exercise prices of the options ($6.89 and $18.93), demonstrating a strong return on the equity compensation.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which suggests a disciplined approach to managing personal equity holdings and mitigates concerns about opportunistic insider trading.

Negatives

• The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is typically a routine part of executive compensation monetization.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an executive's personal equity management.

Stakeholder Impact

• Shareholders may note the executive's monetization of equity, which is a common practice for compensation. The pre-planned nature of the transactions under Rule 10b5-1 typically reduces concerns about opportunistic selling.

Key Dates

Recommendation

The filing details routine insider transactions by the Chief Financial Officer under a pre-established Rule 10b5-1 trading plan. While significant shares were sold, these were preceded by option exercises, indicating monetization of vested equity compensation rather than a change in fundamental outlook. Such planned transactions typically do not warrant a change in investment recommendation based solely on this filing.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, CFO, Alexandra Balcom, Rule 10b5-1, Equity Compensation, Stock Sale